WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) have been assigned an average rating of “Moderate Buy” from the fifteen analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and fourteen have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $26.4118.

WVE has been the topic of several analyst reports. Mizuho lifted their target price on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. New Street Research set a $13.00 target price on shares of WAVE Life Sciences in a report on Thursday, June 11th. Bank of America lowered their target price on shares of WAVE Life Sciences from $38.00 to $21.00 and set a “buy” rating on the stock in a report on Friday, March 27th. Citigroup lowered their target price on shares of WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, May 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Monday, April 20th.

WAVE Life Sciences Stock Performance

NASDAQ WVE opened at $5.83 on Friday. The firm has a market cap of $1.12 billion, a PE ratio of -5.50 and a beta of -1.33. WAVE Life Sciences has a one year low of $5.02 and a one year high of $21.73. The firm’s fifty day moving average is $6.51 and its two-hundred day moving average is $10.90.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.21. The company had revenue of $38.25 million for the quarter, compared to analyst estimates of $8.45 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%. Research analysts predict that WAVE Life Sciences will post -1.1 earnings per share for the current year.

Institutional Trading of WAVE Life Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its holdings in WAVE Life Sciences by 1.5% during the fourth quarter. Deutsche Bank AG now owns 95,706 shares of the company’s stock worth $1,627,000 after buying an additional 1,441 shares in the last quarter. AlphaCentric Advisors LLC boosted its holdings in WAVE Life Sciences by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 29,175 shares of the company’s stock worth $212,000 after buying an additional 1,585 shares in the last quarter. First Trust Advisors LP boosted its holdings in WAVE Life Sciences by 15.7% during the first quarter. First Trust Advisors LP now owns 13,518 shares of the company’s stock worth $98,000 after buying an additional 1,830 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in WAVE Life Sciences by 645.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock worth $38,000 after buying an additional 1,942 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in WAVE Life Sciences by 32.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock worth $138,000 after buying an additional 1,972 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.